We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$5.72B 30.41%
50,057,277
– –
INCY icon
2
Incyte
INCY
$25.5B
$2.79B 14.84%
31,976,873
+316
+0% +$27K
ONC
3
BeOne Medicines Ltd
ONC
$33.8B
$1.95B 10.38%
11,777,285
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.43B
$1.75B 9.29%
40,854,586
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$893M 4.75%
8,258,068
– –
KOD icon
6
Kodiak Sciences
KOD
$2.4B
$795M 4.23%
11,047,289
+1,902,173
+21% +$69.2M
AMRN
7
Amarin Corp
AMRN
$299M
$740M 3.93%
1,724,834
-352,380
-17% -$134M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$642M 3.41%
7,589,294
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.7B
$472M 2.51%
3,390,270
– –
EXAS
10
DELISTED
Exact Sciences
EXAS
$239M 1.27%
+2,585,791
New +$227M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$168M 0.9%
1,307,220
– –
ARGX icon
12
argenx
ARGX
$55.1B
$164M 0.87%
1,019,557
– –
DBVT
13
DBV Technologies
DBVT
$800M
$156M 0.83%
1,461,426
+910,470
+165% +$72.8M
NVTA
14
DELISTED
Invitae Corporation
NVTA
$147M 0.78%
9,097,165
+304,487
+3% +$5.38M
HRTX icon
15
Heron Therapeutics
HRTX
$91.6M
$141M 0.75%
6,018,104
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$18.2B
$135M 0.72%
1,254,243
-161,040
-11% -$16.9M
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$129M 0.69%
1,774,234
+256,997
+17% +$15.6M
IGMS
18
DELISTED
IGM Biosciences
IGMS
$120M 0.64%
3,144,000
– –
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.5B
$107M 0.57%
1,169,278
– –
RARX
20
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$98.3M 0.52%
2,093,839
-251,657
-11% -$11.1M
PRNB
21
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$97.9M 0.52%
1,787,957
+133,928
+8% +$5M
AXSM icon
22
Axsome Therapeutics
AXSM
$11.9B
$85.8M 0.46%
829,757
+57,471
+7% +$2.32M
ZYME icon
23
Zymeworks
ZYME
$1.62B
$77.7M 0.41%
1,708,472
– –
TCDA
24
DELISTED
Tricida, Inc. Common Stock
TCDA
$74.3M 0.4%
1,969,905
– –
RYTM icon
25
Rhythm Pharmaceuticals
RYTM
$7.3B
$62.2M 0.33%
2,708,200
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Baker Bros. Advisors held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Baker Bros. Advisors added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Baker Bros. Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Baker Bros. Advisors fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 18 in Q4 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.